

Patrick F Augustijns

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8423787/publications.pdf>

Version: 2024-02-01

366
papers

19,416
citations

8755

75
h-index

19190

118
g-index

377
all docs

377
docs citations

377
times ranked

16211
citing authors

#	ARTICLE	IF	CITATIONS
1	Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 170, 106098.	4.0	29
2	Fasted intestinal solubility limits and distributions applied to the biopharmaceutics and developability classification systems. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 170, 160-169.	4.3	9
3	The Influence of Fed State Lipolysis Inhibition on the Intraluminal Behaviour and Absorption of Fenofibrate from a Lipid-Based Formulation. <i>Pharmaceutics</i> , 2022, 14, 119.	4.5	2
4	Application of In Vivo Imaging Techniques and Diagnostic Tools in Oral Drug Delivery Research. <i>Pharmaceutics</i> , 2022, 14, 801.	4.5	4
5	Practical and operational considerations related to paediatric oral drug formulation: An industry survey. <i>International Journal of Pharmaceutics</i> , 2022, 618, 121670.	5.2	12
6	The effect of esomeprazole on the upper GI tract release and systemic absorption of mesalazine from colon targeted formulations. <i>International Journal of Pharmaceutics</i> , 2022, 619, 121701.	5.2	3
7	Integration of advanced methods and models to study drug absorption and related processes: An UNGAP perspective. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 172, 106100.	4.0	12
8	HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect. <i>Antiviral Research</i> , 2022, 202, 105311.	4.1	8
9	The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2022, 13, 719.	12.8	86
10	Investigating the Mechanisms behind the Positive Food Effect of Abiraterone Acetate: In Vitro and Rat In Situ Studies. <i>Pharmaceutics</i> , 2022, 14, 952.	4.5	3
11	Orlistat disposition in the human jejunum and the effect of lipolysis inhibition on bile salt concentrations and composition. <i>International Journal of Pharmaceutics</i> , 2022, 621, 121807.	5.2	1
12	Structured solubility behaviour in bioequivalent fasted simulated intestinal fluids. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 176, 108-121.	4.3	4
13	Association between duodenal bile salts and gastric emptying in patients with functional dyspepsia. <i>Gut</i> , 2021, 70, 2208.2-2210.	12.1	9
14	Insight into the Colonic Disposition of Sulindac in Humans. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 259-267.	3.3	9
15	Codeine induces increased resistance at the esophagogastric junction but has no effect on motility and bolus flow in the pharynx and upper esophageal sphincter in healthy volunteers: A randomized, double-blind, placebo-controlled, crossover trial. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14041.	3.0	9
16	Proton Pump Inhibitors Reduce Duodenal Eosinophilia, Mast Cells, and Permeability in Patients With Functional Dyspepsia. <i>Gastroenterology</i> , 2021, 160, 1521-1531.e9.	1.3	55
17	Exploring the Impact of Intestinal Fluid Components on the Solubility and Supersaturation of Danazol. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 2479-2488.	3.3	2
18	Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring. <i>Pharmaceutics</i> , 2021, 13, 161.	4.5	18

#	ARTICLE	IF	CITATIONS
19	Local immune response to food antigens drives meal-induced abdominal pain. <i>Nature</i> , 2021, 590, 151-156.	27.8	153
20	Adaptations in gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 225-237.	8.1	49
21	Chloroquine, an Anti-Malaria Drug as Effective Prevention for Hantavirus Infections. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 580532.	3.9	5
22	Leveraging Oral Drug Development to a Next Level: Impact of the IMI-Funded OrBiTo Project on Patient Healthcare. <i>Frontiers in Medicine</i> , 2021, 8, 480706.	2.6	2
23	Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. <i>Advanced Drug Delivery Reviews</i> , 2021, 171, 289-331.	13.7	84
24	Crystallization Kinetics in Fasted-State Simulated and Aspirated Human Intestinal Fluids. <i>Crystal Growth and Design</i> , 2021, 21, 2807-2820.	3.0	8
25	Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 162, 105812.	4.0	137
26	An Assessment of Occasional Bio-Inequivalence for BCS1 and BCS3 Drugs: What are the Underlying Reasons?. <i>Journal of Pharmaceutical Sciences</i> , 2021, , .	3.3	1
27	Effect of obesity on gastrointestinal transit, pressure and pH using a wireless motility capsule. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 167, 1-8.	4.3	16
28	The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. <i>EBioMedicine</i> , 2021, 72, 103595.	6.1	91
29	Specific contributions of segmental transit times to gut microbiota composition. <i>Gut</i> , 2021, , gutjnl-2021-325916.	12.1	4
30	Duodenal Dysbiosis and Relation to the Efficacy of Proton Pump Inhibitors in Functional Dyspepsia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13609.	4.1	23
31	Codeine delays gastric emptying through inhibition of gastric motility as assessed with a novel diagnostic intragastric balloon catheter. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13733.	3.0	13
32	Biopredictive in vitro testing methods to assess intestinal drug absorption from supersaturating dosage forms. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 56, 101275.	3.0	6
33	The influence of gastric motility on the intraluminal behavior of fosamprenavir. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 142, 105117.	4.0	11
34	Relationship between bile salts, bacterial translocation, and duodenal mucosal integrity in functional dyspepsia. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13788.	3.0	22
35	Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 26955-26965.	7.1	240
36	Exploring the Effect of Esomeprazole on Gastric and Duodenal Fluid Volumes and Absorption of Ritonavir. <i>Pharmaceutics</i> , 2020, 12, 670.	4.5	15

#	ARTICLE	IF	CITATIONS
37	Multidimensional analysis of human intestinal fluid composition. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 153, 226-240.	4.3	16
38	Development of a HILIC-MS/MS method for the quantification of histamine and its main metabolites in human urine samples. <i>Talanta</i> , 2020, 220, 121328.	5.5	21
39	Molecular Dynamics Simulations on Interindividual Variability of Intestinal Fluids: Impact on Drug Solubilization. <i>Molecular Pharmaceutics</i> , 2020, 17, 3837-3844.	4.6	18
40	Unraveling the behavior of oral drug products inside the human gastrointestinal tract using the aspiration technique: History, methodology and applications. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 155, 105517.	4.0	18
41	Reply to "Comment on López-Yerena et al. "Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats"™ <i>Pharmaceutics</i> 2020, 12, 134" <i>Pharmaceutics</i> , 2020, 12, 1221.	4.5	2
42	Application of the Gastrointestinal Simulator (GIS) Coupled with In Silico Modeling to Measure the Impact of Coca-Cola® on the Luminal and Systemic Behavior of Loratadine (BCS Class 2b). <i>Pharmaceutics</i> , 2020, 12, 566.	4.5	8
43	Exploring the impact of real-life dosing conditions on intraluminal and systemic concentrations of atazanavir in parallel with gastric motility recording in healthy subjects. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 150, 66-76.	4.3	11
44	Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats. <i>Pharmaceutics</i> , 2020, 12, 134.	4.5	21
45	Impact of gastrointestinal physiology on drug absorption in special populations" "An UNGAP review. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 147, 105280.	4.0	142
46	Insight into the colonic disposition of celecoxib in humans. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 145, 105242.	4.0	12
47	The effect of reduced gastric acid secretion on the gastrointestinal disposition of a ritonavir amorphous solid dispersion in fasted healthy volunteers: an in vivo - in vitro investigation.. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 151, 105377.	4.0	14
48	Biorelevant Two-Stage In Vitro Testing for rDCS Classification and in PBPK Modeling" "Case Example Ritonavir. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2512-2526.	3.3	14
49	Intestinal phase-II metabolism of quercetin in HT29 cells, 3D human intestinal tissues and in healthy volunteers: a qualitative comparison using LC-IMS-MS and LC-HRMS. <i>Xenobiotica</i> , 2019, 49, 945-952.	1.1	7
50	Immobilizing sulfotransferase 1A1 on magnetic microparticles and their evaluation using capillary electrophoresis. <i>Electrophoresis</i> , 2019, 40, 2271-2276.	2.4	6
51	Interplay of Supersaturation and Solubilization: Lack of Correlation between Concentration-Based Supersaturation Measurements and Membrane Transport Rates in Simulated and Aspirated Human Fluids. <i>Molecular Pharmaceutics</i> , 2019, 16, 5042-5053.	4.6	40
52	The effect of chitosan on the bioaccessibility and intestinal permeability of acyclovir. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 136, 147-155.	4.3	14
53	Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 137, 104967.	4.0	222
54	Biorelevant dissolution testing of a weak base: Interlaboratory reproducibility and investigation of parameters controlling in vitro precipitation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 140, 141-148.	4.3	33

#	ARTICLE	IF	CITATIONS
55	The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 134, 31-59.	4.0	224
56	Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: An UNGAP review. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 134, 153-175.	4.0	146
57	Co-existing colloidal phases of human duodenal aspirates: Intraindividual fluctuations and interindividual variability in relation to molecular composition. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 170, 22-29.	2.8	13
58	In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 136, 70-83.	4.3	91
59	Gastric and Duodenal Diclofenac Concentrations in Healthy Volunteers after Intake of the FDA Standard Meal: In Vivo Observations and in Vitro Explorations. <i>Molecular Pharmaceutics</i> , 2019, 16, 573-582.	4.6	14
60	Preoperative administration of the 5-HT ₄ receptor agonist prucalopride reduces intestinal inflammation and shortens postoperative ileus via cholinergic enteric neurons. <i>Gut</i> , 2019, 68, 1406-1416.	12.1	69
61	Predicting iron absorption from an effervescent iron supplement in obese patients before and after Roux-en-Y gastric bypass: a preliminary study. <i>Journal of Trace Elements in Medicine and Biology</i> , 2019, 52, 68-73.	3.0	4
62	Effect of Cryopreservation on Enzyme and Transporter Activities in Suspended and Sandwich Cultured Rat Hepatocytes. <i>AAPS Journal</i> , 2018, 20, 33.	4.4	5
63	Drug permeability profiling using cell-free permeation tools: Overview and applications. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 119, 219-233.	4.0	139
64	Iron deficiency after bariatric surgery: what is the real problem?. <i>Proceedings of the Nutrition Society</i> , 2018, 77, 445-455.	1.0	50
65	The effect of 2-hydroxypropyl- β -cyclodextrin on the intestinal permeation through mucus. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 114, 238-244.	4.0	17
66	An improved design to capture magnetic microparticles for capillary electrophoresis based immobilized microenzyme reactors. <i>Electrophoresis</i> , 2018, 39, 981-988.	2.4	14
67	Extra collagen overlay prolongs the differentiated phenotype in sandwich-cultured rat hepatocytes. <i>Journal of Pharmacological and Toxicological Methods</i> , 2018, 90, 31-38.	0.7	6
68	Assessment of Passive Intestinal Permeability Using an Artificial Membrane Insert System. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 250-256.	3.3	40
69	Identification of phase-II metabolites of flavonoids by liquid chromatography-ion-mobility spectrometry-mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 471-482.	3.7	31
70	The artificial membrane insert system as predictive tool for formulation performance evaluation. <i>International Journal of Pharmaceutics</i> , 2018, 537, 22-29.	5.2	28
71	Advances in Capillary Electrophoretically Mediated Microanalysis for On-line Enzymatic and Derivatization Reactions. <i>Electrophoresis</i> , 2018, 39, 97-110.	2.4	36
72	Altered duodenal bile salt concentration and receptor expression in functional dyspepsia. <i>United European Gastroenterology Journal</i> , 2018, 6, 1347-1355.	3.8	27

#	ARTICLE	IF	CITATIONS
73	Opening the black box: Gastric motility, as assessed by the novel vipun gastric monitoring system, is a surrogate measurement for gastric emptying. <i>Clinical Nutrition</i> , 2018, 37, S34.	5.0	0
74	Intestinal disposition of quercetin and its phase-II metabolites after oral administration in healthy volunteers. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 1002-1008.	2.4	32
75	Human intestinal fluid layer separation: The effect on colloidal structures & solubility of lipophilic compounds. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 129, 104-110.	4.3	17
76	Linking the concentrations of itraconazole and 2-hydroxypropyl- β -cyclodextrin in human intestinal fluids after oral intake of Sporanox [®] . <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 132, 231-236.	4.3	12
77	Exploring gastric drug absorption in fasted and fed state rats. <i>International Journal of Pharmaceutics</i> , 2018, 548, 636-641.	5.2	10
78	Gastric fluid composition in a paediatric population: Age-dependent changes relevant for gastrointestinal drug disposition. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 123, 301-311.	4.0	35
79	The BioGIT System: a Valuable In Vitro Tool to Assess the Impact of Dose and Formulation on Early Exposure to Low Solubility Drugs After Oral Administration. <i>AAPS Journal</i> , 2018, 20, 71.	4.4	30
80	Human intestinal fluid factors affecting intestinal drug permeation in vitro. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 121, 338-346.	4.0	17
81	Evaluation of immobilized hFMO3 on magnetic nanoparticles by capillary zone electrophoresis. <i>Bioanalysis</i> , 2017, 9, 289-296.	1.5	6
82	Development of enteric-coated fixed dose combinations of amorphous solid dispersions of ezetimibe and lovastatin: Investigation of formulation and process parameters. <i>International Journal of Pharmaceutics</i> , 2017, 520, 49-58.	5.2	11
83	Atmospheric Pressure Ionization Using a High Voltage Target Compared to Electrospray Ionization. <i>Journal of the American Society for Mass Spectrometry</i> , 2017, 28, 286-293.	2.8	17
84	Gastrointestinal behavior of itraconazole in humans – Part 1: Supersaturation from a solid dispersion and a cyclodextrin-based solution. <i>International Journal of Pharmaceutics</i> , 2017, 525, 211-217.	5.2	27
85	An atmospheric pressure ionization source using a high voltage target compared to electrospray ionization for the LC/MS analysis of pharmaceutical compounds. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 142, 225-231.	2.8	15
86	Gastrointestinal behavior of itraconazole in humans – Part 2: The effect of intraluminal dilution on the performance of a cyclodextrin-based solution. <i>International Journal of Pharmaceutics</i> , 2017, 526, 235-243.	5.2	30
87	Evaluation of real-life dosing of oral medicines with respect to fluid and food intake in a Dutch-speaking population. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 467-474.	1.5	11
88	Gastrointestinal and Systemic Disposition of Diclofenac under Fasted and Fed State Conditions Supporting the Evaluation of <i>In Vitro</i> Predictive Tools. <i>Molecular Pharmaceutics</i> , 2017, 14, 4220-4232.	4.6	28
89	Exploring drug solubility in fasted human intestinal fluid aspirates: Impact of inter-individual variability, sampling site and dilution. <i>International Journal of Pharmaceutics</i> , 2017, 528, 471-484.	5.2	20
90	Inter-Subject Variability in OCT1 Activity in 27 Batches of Cryopreserved Human Hepatocytes and Association with OCT1 mRNA Expression and Genotype. <i>Pharmaceutical Research</i> , 2017, 34, 1309-1319.	3.5	4

#	ARTICLE	IF	CITATIONS
91	The Effect of Sparkling Water on Intraluminal Formulation Behavior and Systemic Drug Performance. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2472-2482.	3.3	15
92	Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities. <i>International Journal of Pharmaceutics</i> , 2017, 519, 79-97.	5.2	81
93	Trapping magnetic nanoparticles for in-line capillary electrophoresis in a liquid based capillary coolant system. <i>Talanta</i> , 2017, 164, 148-153.	5.5	14
94	Flexible nano- and microliter injections on a single liquid chromatography–mass spectrometry system: Minimizing sample preparation and maximizing linear dynamic range. <i>Journal of Chromatography A</i> , 2017, 1524, 101-107.	3.7	4
95	<i>In Silico</i> Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole. <i>Molecular Pharmaceutics</i> , 2017, 14, 4321-4333.	4.6	59
96	Role of the OATP Transporter Family and a Benzbromarone-Sensitive Efflux Transporter in the Hepatocellular Disposition of Vincristine. <i>Pharmaceutical Research</i> , 2017, 34, 2336-2348.	3.5	10
97	Gastric and Duodenal Ethanol Concentrations after Intake of Alcoholic Beverages in Postprandial Conditions. <i>Molecular Pharmaceutics</i> , 2017, 14, 4202-4208.	4.6	4
98	Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study. <i>Molecular Pharmaceutics</i> , 2017, 14, 4192-4201.	4.6	69
99	The Effect of the Acid Pocket of Healthy Volunteers and Gerd Patients on Epithelial Integrity. <i>Gastroenterology</i> , 2017, 152, S235-S236.	1.3	0
100	Association Between Luminal Bile Salt Content and Duodenal Mucosal Integrity in Functional Dyspepsia. <i>Gastroenterology</i> , 2017, 152, S167.	1.3	3
101	The impact of guest compounds on cyclodextrin aggregation behavior: A series of structurally related parabens. <i>International Journal of Pharmaceutics</i> , 2017, 529, 442-450.	5.2	18
102	Development of a sensitive and quantitative UHPLC-MS/MS method to study the whole-body uptake of pharmaceuticals in zebrafish. <i>Talanta</i> , 2017, 174, 780-788.	5.5	11
103	Micronutrient intake, from diet and supplements, and association with status markers in pre- and post-RYGB patients. <i>Clinical Nutrition</i> , 2017, 36, 1175-1181.	5.0	42
104	Exploring the link between gastric motility and intragastric drug distribution in man. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 112, 75-84.	4.3	25
105	The dynamic gastric environment and its impact on drug and formulation behaviour. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 96, 207-231.	4.0	73
106	The Influence of Prebiotic Arabinosyloxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2016, 11, e0153893.	2.5	74
107	Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 183-188.	2.0	33
108	A liquid chromatography – tandem mass spectrometry method to measure a selected panel of uremic retention solutes derived from endogenous and colonic microbial metabolism. <i>Analytica Chimica Acta</i> , 2016, 936, 149-156.	5.4	40

#	ARTICLE	IF	CITATIONS
109	Hepatic Clearance Prediction of Nine Human Immunodeficiency Virus Protease Inhibitors in Rat. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 846-853.	3.3	5
110	Clearance Prediction of HIV Protease Inhibitors in Man: Role of Hepatic Uptake. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 854-863.	3.3	17
111	A Tribute to Ronald T. Borchardt "Teacher, Mentor, Scientist, Colleague, Leader, Friend, and Family Man. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 370-385.	3.3	4
112	Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3479-3487.	6.1	144
113	Gastrointestinal Behavior of Weakly Acidic BCS Class II Drugs in Man "Case Study of Diclofenac Potassium. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 687-696.	3.3	40
114	Recent advances in CE mediated microanalysis for enzymatic and derivatization reactions. <i>Electrophoresis</i> , 2016, 37, 56-65.	2.4	18
115	Metabolism, Protein Binding, and Renal Clearance of Microbiota "Derived p-Cresol in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1136-1144.	4.5	57
116	Supersaturation and Precipitation of Posaconazole Upon Entry in the Upper Small Intestine in Humans. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2677-2684.	3.3	92
117	The Effect of Food on the Intraluminal Behavior of Abiraterone Acetate in Man. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2974-2981.	3.3	36
118	Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 953-963.	1.9	21
119	Bile Salt Micelles and Phospholipid Vesicles Present in Simulated and Human Intestinal Fluids: Structural Analysis by Flow Field "Flow Fractionation/Multiangle Laser Light Scattering. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2832-2839.	3.3	36
120	A Tribute to Dr. Marcus E. Brewster. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2466-2467.	3.3	0
121	Gastrointestinal and Systemic Monitoring of Posaconazole in Humans After Fasted and Fed State Administration of a Solid Dispersion. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2904-2912.	3.3	43
122	An In-Depth View into Human Intestinal Fluid Colloids: Intersubject Variability in Relation to Composition. <i>Molecular Pharmaceutics</i> , 2016, 13, 3484-3493.	4.6	49
123	Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 109, 122-129.	4.3	49
124	Drug disposition before and after gastric bypass: fenofibrate and posaconazole. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1325-1332.	2.4	24
125	Displacement of itraconazole from cyclodextrin complexes in biorelevant media: In vitro evaluation of supersaturation and precipitation behavior. <i>International Journal of Pharmaceutics</i> , 2016, 511, 680-687.	5.2	26
126	In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT. <i>International Journal of Pharmaceutics</i> , 2016, 515, 352-358.	5.2	29

#	ARTICLE	IF	CITATIONS
127	In vitro and in vivo investigation of the gastrointestinal behavior of simvastatin. International Journal of Pharmaceutics, 2016, 510, 296-303.	5.2	18
128	Self-Assembly of Cyclodextrins and Their Complexes in Aqueous Solutions. Journal of Pharmaceutical Sciences, 2016, 105, 2556-2569.	3.3	111
129	Ethanol concentrations in the human gastrointestinal tract after intake of alcoholic beverages. European Journal of Pharmaceutical Sciences, 2016, 86, 91-95.	4.0	31
130	Transport-Metabolism Interplay of Atazanavir in Rat Hepatocytes. Drug Metabolism and Disposition, 2016, 44, 389-397.	3.3	5
131	Enhanced performance for the analysis of prostaglandins and thromboxanes by liquid chromatography-tandem mass spectrometry using a new atmospheric pressure ionization source. Journal of Chromatography A, 2016, 1440, 260-265.	3.7	25
132	The influence of renal transplantation on retained microbial human co-metabolites. Nephrology Dialysis Transplantation, 2016, 31, 1721-1729.	0.7	35
133	The Influence of Nebulized Drugs on Nasal Ciliary Activity. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2016, 29, 378-385.	1.4	12
134	An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: Design, implementation, and evaluation. European Journal of Pharmaceutical Sciences, 2016, 82, 106-114.	4.0	60
135	Histamine Receptor H1 Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. Gastroenterology, 2016, 150, 875-887.e9.	1.3	263
136	Effect of Age on The Hepatocellularity Number for Wistar rats. Drug Metabolism and Disposition, 2016, 44, 944-947.	3.3	4
137	The Influence of CKD on Colonic Microbial Metabolism. Journal of the American Society of Nephrology: JASN, 2016, 27, 1389-1399.	6.1	106
138	Characterization of Human Duodenal Fluids in Fasted and Fed State Conditions. Journal of Pharmaceutical Sciences, 2016, 105, 673-681.	3.3	178
139	One drop chemical derivatization DESI-MS analysis for metabolite structure identification. Journal of Mass Spectrometry, 2015, 50, 871-878.	1.6	6
140	Verapamil hepatic clearance in four preclinical rat models: towards activity-based scaling. Biopharmaceutics and Drug Disposition, 2015, 36, 462-480.	1.9	10
141	FP594 TARGETING MICROBIOTA DERIVED UREMIC RETENTION SOLUTES WITH ANTIBIOTICS. Nephrology Dialysis Transplantation, 2015, 30, iii271-iii271.	0.7	0
142	Barriers in the Approach of Obese Patients Undergoing Bariatric Surgery in Flemish Hospitals. Obesity Surgery, 2015, 25, 2153-2158.	2.1	6
143	Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential. European Journal of Pharmaceutical Sciences, 2015, 77, 40-47.	4.0	82
144	Unbound Ritonavir Concentrations in Rat and Human Hepatocytes. Journal of Pharmaceutical Sciences, 2015, 104, 2378-2387.	3.3	8

#	ARTICLE	IF	CITATIONS
145	Evaluation of fasted and fed state simulated and human intestinal fluids as solvent system in the Ussing chambers model to explore food effects on intestinal permeability. <i>International Journal of Pharmaceutics</i> , 2015, 478, 736-744.	5.2	42
146	Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: In vitro, rat in situ and human in vivo studies. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 90, 1-7.	4.3	62
147	Intestinal behavior of the ester prodrug tenofovir DF in humans. <i>International Journal of Pharmaceutics</i> , 2015, 485, 131-137.	5.2	25
148	In vitro disposition profiling of heterocyclic compounds. <i>International Journal of Pharmaceutics</i> , 2015, 491, 78-90.	5.2	2
149	Drug disposition and modelling before and after gastric bypass: immediate and controlled release metoprolol formulations. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1021-1030.	2.4	25
150	Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1151-1160.	3.5	15
151	Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1525-1533.	4.5	59
152	Evaluation of fasted state human intestinal fluid as apical solvent system in the Caco-2 absorption model and comparison with FaSSIF. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 67, 126-135.	4.0	34
153	Age-Dependent Activity of the Uptake Transporters Ntcp and Oatp1b2 in Male Rat Hepatocytes: From Birth Till Adulthood. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1-8.	3.3	17
154	In situ perfusion in rodents to explore intestinal drug absorption: Challenges and opportunities. <i>International Journal of Pharmaceutics</i> , 2015, 478, 665-681.	5.2	63
155	Metabonomics and Drug Development. <i>Methods in Molecular Biology</i> , 2015, 1277, 195-207.	0.9	7
156	The Influence of Dietary Protein Intake on Mammalian Tryptophan and Phenolic Metabolites. <i>PLoS ONE</i> , 2015, 10, e0140820.	2.5	77
157	Development of thiolated poly(acrylic acid) microparticles for the nasal administration of exenatide. <i>Drug Development and Industrial Pharmacy</i> , 2014, 40, 1677-1682.	2.0	14
158	Hepatobiliary and intestinal elimination of darunavir in an integrated preclinical rat model. <i>Xenobiotica</i> , 2014, 44, 489-497.	1.1	3
159	The Use of Supersaturation for the Vaginal Application of Microbicides: A Case Study with Dapivirine. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 3696-3703.	3.3	4
160	Resolving intraluminal drug and formulation behavior: Gastrointestinal concentration profiling in humans. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 61, 2-10.	4.0	34
161	In vitro models for the prediction of in vivo performance of oral dosage forms. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 57, 342-366.	4.0	297
162	Iron Deficiency After Roux-en-Y Gastric Bypass: Insufficient Iron Absorption from Oral Iron Supplements. <i>Obesity Surgery</i> , 2014, 24, 56-61.	2.1	58

#	ARTICLE	IF	CITATIONS
163	Classification of the Crystallization Behavior of Amorphous Active Pharmaceutical Ingredients in Aqueous Environments. <i>Pharmaceutical Research</i> , 2014, 31, 969-982.	3.5	71
164	A review of drug solubility in human intestinal fluids: Implications for the prediction of oral absorption. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 57, 322-332.	4.0	159
165	In vivo methods for drug absorption “Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 57, 99-151.	4.0	226
166	Hepatocyte-based in vitro model for assessment of drug-induced cholestasis. <i>Toxicology and Applied Pharmacology</i> , 2014, 274, 124-136.	2.8	79
167	Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diarylthiazine NNRTI against HIV-1. <i>Antiviral Research</i> , 2014, 101, 113-121.	4.1	20
168	Vaginal Expression of Efflux Transporters and the Potential Impact on the Disposition of Microbicides in Vitro and in Rabbits. <i>Molecular Pharmaceutics</i> , 2014, 11, 4405-4414.	4.6	14
169	Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398. <i>International Journal of Pharmaceutics</i> , 2014, 475, 238-244.	5.2	24
170	Straightforward entry to pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones and their ADME properties. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 3947-3956.	3.0	11
171	Human and simulated intestinal fluids as solvent systems to explore food effects on intestinal solubility and permeability. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 63, 178-186.	4.0	41
172	Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2014, 15, 87.	1.8	48
173	Do Roux-en-Y gastric bypass patients meet the dietary guidelines?. <i>Archives of Public Health</i> , 2014, 72, .	2.4	0
174	Confocal Imaging with a Fluorescent Bile Acid Analogue Closely Mimicking Hepatic Taurocholate Disposition. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1872-1881.	3.3	41
175	Medication Cost is Significantly Reduced After Roux-en-Y Gastric Bypass in Obese Patients. <i>Obesity Surgery</i> , 2014, 24, 1896-1903.	2.1	28
176	Gastrointestinal transfer: In vivo evaluation and implementation in in vitro and in silico predictive tools. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 63, 233-242.	4.0	63
177	Lipid-Based Formulations Solidified Via Adsorption onto the Mesoporous Carrier Neusilin® US2: Effect of Drug Type and Formulation Composition on In Vitro Pharmaceutical Performance. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1734-1746.	3.3	56
178	Oral biopharmaceutics tools “Time for a new initiative” An introduction to the IMI project OrBiTo. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 57, 292-299.	4.0	91
179	Toxicity and intracellular accumulation of bile acids in sandwich-cultured rat hepatocytes: Role of glycine conjugates. <i>Toxicology in Vitro</i> , 2014, 28, 218-230.	2.4	39
180	Editorial: In Memoriam Dr. Marcus Brewster. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 3808-3809.	3.3	1

#	ARTICLE	IF	CITATIONS
181	Evaluation of gastrointestinal drug supersaturation and precipitation: Strategies and issues. <i>International Journal of Pharmaceutics</i> , 2013, 453, 25-35.	5.2	212
182	Site dependent intestinal absorption of darunavir and its interaction with ketoconazole. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 51-56.	4.0	11
183	Biopharmaceutical profiling of a pyrido[4,3-d] pyrimidine compound library. <i>International Journal of Pharmaceutics</i> , 2013, 455, 19-30.	5.2	9
184	Solubility Profiling of HIV Protease Inhibitors in Human Intestinal Fluids. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3800-3807.	3.3	26
185	In Situ FT-IR Investigation of Etravirine Speciation in Pores of SBA-15 Ordered Mesoporous Silica Material upon Contact with Water. <i>Molecular Pharmaceutics</i> , 2013, 10, 567-573.	4.6	18
186	Screening protocol for identifying inorganic oxides with anti-oxidant and pro-oxidant activity for biomedical, environmental and food preservation applications. <i>RSC Advances</i> , 2013, 3, 900-909.	3.6	4
187	PXR/CYP3A4-Humanized Mice for Studying Drug-Drug Interactions Involving Intestinal P-Glycoprotein. <i>Molecular Pharmaceutics</i> , 2013, 10, 1056-1062.	4.6	31
188	Structure-Based Identification of OATP1B1/3 Inhibitors. <i>Molecular Pharmacology</i> , 2013, 83, 1257-1267.	2.3	110
189	Exploring food effects on indinavir absorption with human intestinal fluids in the mouse intestine. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 27-32.	4.0	41
190	Sandwich-cultured hepatocytes: utility for <i>in vitro</i> exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 589-616.	3.3	110
191	Synthesis of 1-substituted epibatidine analogues and their <i>in vitro</i> and <i>in vivo</i> evaluation as ± 4 nicotinic acetylcholine receptor ligands. <i>RSC Advances</i> , 2013, 4, 2226-2234.	3.6	4
192	MiniCD4 Microbicide Prevents HIV Infection of Human Mucosal Explants and Vaginal Transmission of SHIV162P3 in Cynomolgus Macaques. <i>PLoS Pathogens</i> , 2012, 8, e1003071.	4.7	32
193	Solubilizing agents in nasal formulations and their effect on ciliary beat frequency. <i>Toxicology in Vitro</i> , 2012, 26, 150-156.	2.4	14
194	Boosting of HIV Protease Inhibitors by Ritonavir in the Intestine: The Relative Role of Cytochrome P450 and P-Glycoprotein Inhibition Based on Caco-2 Monolayers versus In Situ Intestinal Perfusion in Mice. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1473-1477.	3.3	52
195	Supersaturation in human gastric fluids. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 81, 184-189.	4.3	57
196	Incomplete Desorption of Liquid Excipients Reduces the <i>in Vitro</i> and <i>in Vivo</i> Performance of Self-Emulsifying Drug Delivery Systems Solidified by Adsorption onto an Inorganic Mesoporous Carrier. <i>Molecular Pharmaceutics</i> , 2012, 9, 2750-2760.	4.6	76
197	In vitro profiling of the vaginal permeation potential of anti-HIV microbicides and the influence of formulation excipients. <i>Antiviral Research</i> , 2012, 96, 226-233.	4.1	31
198	Drug precipitation-permeation interplay: Supersaturation in an absorptive environment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 82, 424-428.	4.3	107

#	ARTICLE	IF	CITATIONS
199	Llama Antibody Fragments Have Good Potential for Application as HIV Type 1 Topical Microbicides. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 198-205.	1.1	30
200	Stability of Therapeutic Albumin Solutions Used for Molecular Adsorbent Recirculating System-Based Liver Dialysis. <i>Artificial Organs</i> , 2012, 36, 29-41.	1.9	9
201	Thiolated chitosan nanoparticles for the nasal administration of leuprolide: Bioavailability and pharmacokinetic characterization. <i>International Journal of Pharmaceutics</i> , 2012, 428, 164-170.	5.2	100
202	Supersaturating Drug Delivery Systems: Fast is Not Necessarily Good Enough. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 7-9.	3.3	140
203	Molecular organization of hydrophobic molecules and co-adsorbed water in SBA-15 ordered mesoporous silica material. <i>Physical Chemistry Chemical Physics</i> , 2011, 13, 2706-2713.	2.8	40
204	Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole. <i>Clinical Pharmacokinetics</i> , 2011, 50, 725-734.	3.5	114
205	Food-dependent disintegration of immediate release fosamprenavir tablets: In vitro evaluation using magnetic resonance imaging and a dynamic gastrointestinal system. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 77, 313-319.	4.3	84
206	Excipient-Mediated Supersaturation Stabilization in Human Intestinal Fluids. <i>Molecular Pharmaceutics</i> , 2011, 8, 564-570.	4.6	119
207	Ordered Mesoporous Silica for the Delivery of Poorly Soluble Drugs. , 2011, , 203-219.		6
208	Uptake and Transport Characteristics of Chloroquine in an In-vitro Cell Culture System of the Intestinal Mucosa, Caco-2. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 48, 277-280.	2.4	8
209	Intestinal drug solubility estimation based on simulated intestinal fluids: Comparison with solubility in human intestinal fluids. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 43, 260-269.	4.0	97
210	Determination of OATP-, Ntcp- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 43, 297-307.	4.0	54
211	Early identification of availability issues for poorly water-soluble microbicide candidates in biorelevant media: A case study with saquinavir. <i>Antiviral Research</i> , 2011, 91, 217-223.	4.1	14
212	Equilibrium drug solubility measurements in 96-well plates reveal similar drug solubilities in phosphate buffer pH 6.8 and human intestinal fluid. <i>International Journal of Pharmaceutics</i> , 2011, 405, 132-136.	5.2	34
213	Comparison between 2-hydroxypropyl- β -cyclodextrin and 2-hydroxypropyl- γ -cyclodextrin for inclusion complex formation with danazol. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2011, 71, 137-147.	1.6	7
214	Sodium fluorescein is a probe substrate for hepatic drug transport mediated by OATP1B1 and OATP1B3. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 5018-5030.	3.3	74
215	Preventing release in the acidic environment of the stomach via occlusion in ordered mesoporous silica enhances the absorption of poorly soluble weakly acidic drugs. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4864-4876.	3.3	35
216	Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 222-232.	1.9	61

#	ARTICLE	IF	CITATIONS
217	The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate. <i>International Journal of Pharmaceutics</i> , 2011, 414, 118-124.	5.2	52
218	Safety assessment of thiolated polymers: effect on ciliary beat frequency in human nasal epithelial cells. <i>Drug Development and Industrial Pharmacy</i> , 2011, 37, 1455-1462.	2.0	23
219	Solid state properties of pure UC-781 and solid dispersions with polyvinylpyrrolidone (PVP K30). <i>Journal of Pharmacy and Pharmacology</i> , 2010, 53, 1109-1116.	2.4	14
220	In-vitro nasal drug delivery studies: comparison of derivatised, fibrillar and polymerised collagen matrix-based human nasal primary culture systems for nasal drug delivery studies. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 53, 1447-1456.	2.4	50
221	Influence of the composition of in-vitro azo-reducing systems on the degradation kinetics of the model compound amaranth. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 54, 197-203.	2.4	1
222	Inhibitory effect of fruit extracts on P-glycoprotein-related efflux carriers: an in-vitro screening. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 54, 1213-1219.	2.4	35
223	The effect of food components on the absorption of P-gp substrates: a review. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 55, 153-162.	2.4	67
224	High-speed digital imaging method for ciliary beat frequency measurement. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 57, 521-526.	2.4	44
225	Determination of intraluminal theophylline concentrations after oral intake of an immediate and a slow-release dosage form. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 57, 987-995.	2.4	23
226	Sulfasalazine transport in in-vitro, ex-vivo and in-vivo absorption models: contribution of efflux carriers and their modulation by co-administration of synthetic nature-identical fruit extracts. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 57, 1565-1573.	2.4	25
227	Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 58, 1079-1089.	2.4	140
228	Ex vivo permeability experiments in excised rat intestinal tissue and in vitro solubility measurements in aspirated human intestinal fluids support age-dependent oral drug absorption. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 39, 15-22.	4.0	67
229	Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 41, 623-630.	4.0	180
230	Effects of T cell-induced colonic inflammation on epithelial barrier function. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1322-1331.	1.9	18
231	Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. <i>Biopharmaceutics and Drug Disposition</i> , 2010, 31, 178-188.	1.9	31
232	Validation of a differential <i>in situ</i> perfusion method with mesenteric blood sampling in rats for intestinal drug interaction profiling. <i>Biopharmaceutics and Drug Disposition</i> , 2010, 31, 278-285.	1.9	17
233	Species-Specific Interaction of HIV Protease Inhibitors With Accumulation of Cholyl-Glycylamido-Fluorescein (CGamF) in Sandwich-Cultured Hepatocytes. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 2886-2898.	3.3	18
234	Drug Supersaturation in Simulated Human Intestinal Fluids Representing Different Nutritional States. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 4525-4534.	3.3	88

#	ARTICLE	IF	CITATIONS
235	Comparison of the Complexation between Methylprednisolone and Different Cyclodextrins in Solution by ¹ H-NMR and Molecular Modeling Studies. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 3863-3873.	3.3	25
236	Aging behavior of pharmaceutical formulations of itraconazole on SBA-15 ordered mesoporous silica carrier material. <i>Microporous and Mesoporous Materials</i> , 2010, 130, 154-161.	4.4	85
237	Application of PAMPA-models to predict BBB permeability including efflux ratio, plasma protein binding and physicochemical parameters. <i>International Journal of Pharmaceutics</i> , 2010, 395, 182-197.	5.2	46
238	Potential of amorphous microporous silica for ibuprofen controlled release. <i>International Journal of Pharmaceutics</i> , 2010, 397, 84-91.	5.2	39
239	In Situ Intestinal Perfusion in Knockout Mice Demonstrates Inhibition of Intestinal P-Glycoprotein by Ritonavir Causing Increased Darunavir Absorption. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1407-1410.	3.3	36
240	In Vitro Investigation of the Hepatobiliary Disposition Mechanisms of the Antifungal Agent Micafungin in Humans and Rats. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1848-1856.	3.3	55
241	<i>In Vitro</i> Evaluation of Viability, Integrity, and Inflammation in Genital Epithelia upon Exposure to Pharmaceutical Excipients and Candidate Microbicides. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5105-5114.	3.2	65
242	In Vitro Hepatic Metabolism Explains Higher Clearance of Voriconazole in Children versus Adults: Role of CYP2C19 and Flavin-Containing Monooxygenase 3. <i>Drug Metabolism and Disposition</i> , 2010, 38, 25-31.	3.3	115
243	Solubility Increases Associated with Crystalline Drug Nanoparticles: Methodologies and Significance. <i>Molecular Pharmaceutics</i> , 2010, 7, 1858-1870.	4.6	100
244	Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. <i>Xenobiotica</i> , 2010, 40, 163-176.	1.1	148
245	Growth of Itraconazole Nanofibers in Supersaturated Simulated Intestinal Fluid. <i>Molecular Pharmaceutics</i> , 2010, 7, 905-913.	4.6	19
246	Beneficial effect of antibiotics on ciliary beat frequency of human nasal epithelial cells exposed to bacterial toxins. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 437-443.	2.4	19
247	An improved primary human nasal cell culture for the simultaneous determination of transepithelial transport and ciliary beat frequency. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 883-890.	2.4	19
248	Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2010, 74, 495-502.	4.3	92
249	Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2010, 75, 354-365.	4.3	111
250	Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: Nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. <i>Vaccine</i> , 2010, 28, 6282-6291.	3.8	176
251	INTESTINAL PERFUSION WITH MESENTERIC BLOOD SAMPLING IN WILD-TYPE AND KNOCKOUT MICE. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1334-1337.	3.3	36
252	Itraconazole/TPGS/Aerosil®200 solid dispersions. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 38, 270-278.	4.0	50

#	ARTICLE	IF	CITATIONS
253	Formulate-ability of ten compounds with different physicochemical profiles in SMEDDS. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 38, 479-488.	4.0	58
254	Postprandial Evolution in Composition and Characteristics of Human Duodenal Fluids in Different Nutritional States. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 1177-1192.	3.3	112
255	A screening study of surface stabilization during the production of drug nanocrystals. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2091-2103.	3.3	191
256	Ordered Mesoporous Silica Material SBA-15: A Broad-Spectrum Formulation Platform for Poorly Soluble Drugs. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2648-2658.	3.3	237
257	Supersaturating Drug Delivery Systems: The Answer to Solubility-Limited Oral Bioavailability?. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2549-2572.	3.3	778
258	In vivo, in vitro and in silico methods for small molecule transfer across the BBB. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 4429-4468.	3.3	128
259	Capillary zone electrophoresis method development for the analysis of <i>Hippeastrum</i> hybrid agglutinin samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 563-567.	2.3	5
260	Postprandial Changes in Solubilizing Capacity of Human Intestinal Fluids for BCS Class II Drugs. <i>Pharmaceutical Research</i> , 2009, 26, 1456-1466.	3.5	109
261	Biochemical characterization of malate synthase G of <i>P. aeruginosa</i> . <i>BMC Biochemistry</i> , 2009, 10, 20.	4.4	11
262	Downscaling Drug Nanosuspension Production: Processing Aspects and Physicochemical Characterization. <i>AAPS PharmSciTech</i> , 2009, 10, 44-53.	3.3	52
263	An improved primary human nasal cell culture for the simultaneous determination of transepithelial transport and ciliary beat frequency. <i>Journal of Pharmacy and Pharmacology</i> , 2009, 61, 883-890.	2.4	0
264	Phenyl phosphotriester derivatives of AZT: Variations upon the SATE moiety. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 7321-7329.	3.0	23
265	Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport. <i>International Journal of Pharmaceutics</i> , 2008, 357, 169-179.	5.2	79
266	Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. <i>International Journal of Pharmaceutics</i> , 2008, 364, 64-75.	5.2	611
267	Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection. <i>Virology</i> , 2008, 378, 306-310.	2.4	16
268	Drying of crystalline drug nanosuspensions – The importance of surface hydrophobicity on dissolution behavior upon redispersion. <i>European Journal of Pharmaceutical Sciences</i> , 2008, 35, 127-135.	4.0	179
269	Alternative matrix formers for nanosuspension solidification: Dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion. <i>European Journal of Pharmaceutical Sciences</i> , 2008, 35, 344-353.	4.0	63
270	Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. <i>European Journal of Pharmaceutical Sciences</i> , 2008, 35, 383-396.	4.0	220

#	ARTICLE	IF	CITATIONS
271	High-Throughput Study of Phenytoin Solid Dispersions: Formulation Using an Automated Solvent Casting Method, Dissolution Testing, and Scaling-Up. <i>ACS Combinatorial Science</i> , 2008, 10, 637-643.	3.3	21
272	Physical State of Poorly Water Soluble Therapeutic Molecules Loaded into SBA-15 Ordered Mesoporous Silica Carriers: A Case Study with Itraconazole and Ibuprofen. <i>Langmuir</i> , 2008, 24, 8651-8659.	3.5	212
273	Magnetic field assisted nanoparticle dispersion. <i>Chemical Communications</i> , 2008, , 47-49.	4.1	21
274	The angiotensin converting enzyme inhibitory tripeptides Ile-Pro-Pro and Val-Pro-Pro show increasing permeabilities with increasing physiological relevance of absorption models. <i>Peptides</i> , 2008, 29, 1312-1320.	2.4	69
275	Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 69, 223-230.	4.3	221
276	Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during freeze-drying of drug nanosuspensions " A case study with itraconazole. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 70, 590-596.	4.3	78
277	In Vitro Screening Models to Assess Intestinal Drug Absorption and Metabolism. , 2008, , 182-215.		30
278	Binary Phase Diagram of Tetraethyl Orthosilicate and Carbon Dioxide. <i>Journal of Chemical & Engineering Data</i> , 2008, 53, 2573-2575.	1.9	6
279	A step further in the SATE mononucleotide prodrug approach. <i>Nucleic Acids Symposium Series</i> , 2008, 52, 539-540.	0.3	2
280	Cellular Accumulation of Cholyl-Glycylamido-Fluorescein in Sandwich-Cultured Rat Hepatocytes: Kinetic Characterization, Transport Mechanisms, and Effect of Human Immunodeficiency Virus Protease Inhibitors. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1315-1321.	3.3	31
281	Influence of Essential and Fatty Oils on Ciliary Beat Frequency of Human Nasal Epithelial Cells. <i>American Journal of Rhinology & Allergy</i> , 2008, 22, 130-134.	2.2	25
282	Role of Flavin-Containing Monooxygenase in Oxidative Metabolism of Voriconazole by Human Liver Microsomes. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1119-1125.	3.3	82
283	CADA, a Potential Anti-HIV Microbicide that Specifically Targets the Cellular CD4 Receptor. <i>Current HIV Research</i> , 2008, 6, 246-256.	0.5	18
284	Influence of Neopterin on Ciliary Beat Frequency of Human Nasal Epithelial Cells in vitro. <i>Pteridines</i> , 2008, 19, 79-85.	0.5	0
285	Enhanced release of itraconazole from ordered mesoporous SBA-15 silica materials. <i>Chemical Communications</i> , 2007, , 1375.	4.1	202
286	Tunability of Pore Diameter and Particle Size of Amorphous Microporous Silica for Diffusive Controlled Release of Drug Compounds. <i>Journal of Physical Chemistry C</i> , 2007, 111, 13404-13409.	3.1	41
287	In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: Illustration of intraluminal supersaturation. <i>International Journal of Pharmaceutics</i> , 2007, 336, 302-309.	5.2	62
288	Effect of preservatives on ciliary beat frequency in human nasal epithelial cell culture: Single versus multiple exposure. <i>International Journal of Pharmaceutics</i> , 2007, 338, 64-69.	5.2	33

#	ARTICLE	IF	CITATIONS
289	Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. <i>International Journal of Pharmaceutics</i> , 2007, 338, 198-206.	5.2	118
290	Novel generic UPLC/MS/MS method for high throughput analysis applied to permeability assessment in early Drug Discovery. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 847, 182-187.	2.3	68
291	Parallel Monitoring of Plasma and Intraluminal Drug Concentrations in Man After Oral Administration of Fosamprenavir in the Fasted and Fed State. <i>Pharmaceutical Research</i> , 2007, 24, 1862-1869.	3.5	47
292	Selection of Solvent Systems for Membrane-, Cell- and Tissue-Based Permeability Assessment. , 2007, , 179-220.		1
293	Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: A case study with amprenavir. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 372-383.	3.3	87
294	Stable ciliary activity in human nasal epithelial cells grown in a perfusion system. <i>International Journal of Pharmaceutics</i> , 2005, 292, 157-168.	5.2	11
295	Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire® core. <i>Journal of Controlled Release</i> , 2005, 107, 523-536.	9.9	17
296	In vitro intestinal transport and antihypertensive activity of ACE inhibitory pea and whey digests. <i>International Journal of Food Sciences and Nutrition</i> , 2005, 56, 415-430.	2.8	49
297	Specific Antibody Modulates Absorptive Transport and Metabolic Activation of Benzo[a]pyrene across Caco-2 Monolayers. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 640-646.	2.5	23
298	Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. <i>Xenobiotica</i> , 2005, 35, 1055-1066.	1.1	72
299	The use of human nasal in vitro cell systems during drug discovery and development. <i>Toxicology in Vitro</i> , 2005, 19, 107-122.	2.4	102
300	Usefulness of a novel Caco-2 cell perfusion system. I. in vitro prediction of the absorption potential of passively diffused compounds. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2507-2521.	3.3	41
301	Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers. <i>International Journal of Pharmaceutics</i> , 2004, 274, 221-232.	5.2	141
302	HPLC with programmed wavelength fluorescence detection for the simultaneous determination of marker compounds of integrity and P-gp functionality in the Caco-2 intestinal absorption model. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 34, 971-978.	2.8	44
303	Chiral capillary electrophoretic method for quantification of apomorphine. <i>Journal of Chromatography A</i> , 2004, 1049, 195-203.	3.7	8
304	P-glycoprotein attenuating effect of human intestinal fluid. <i>Pharmaceutical Research</i> , 2003, 20, 900-903.	3.5	32
305	Biological, Pharmaceutical, and Analytical Considerations with Respect to the Transport Media Used in the Absorption Screening System, Caco-2. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 1545-1558.	3.3	93
306	Improvement of the dissolution rate of artemisinin by means of supercritical fluid technology and solid dispersions. <i>International Journal of Pharmaceutics</i> , 2003, 254, 173-181.	5.2	69

#	ARTICLE	IF	CITATIONS
307	Safety-assessment of 3-methoxyquercetin as an antirhinoviral compound for nasal application: effect on ciliary beat frequency. <i>International Journal of Pharmaceutics</i> , 2003, 263, 95-103.	5.2	33
308	Screening of Tanzanian plant extracts for their potential inhibitory effect on P-glycoprotein mediated ef?ux. <i>Phytotherapy Research</i> , 2003, 17, 459-464.	5.8	14
309	Metabolism of stevioside in pigs and intestinal absorption characteristics of stevioside, rebaudioside A and steviol. <i>Food and Chemical Toxicology</i> , 2003, 41, 1599-1607.	3.6	96
310	Intestinal Absorption Enhancement of the Ester Prodrug Tenofovir Disoproxil Fumarate through Modulation of the Biochemical Barrier by Defined Ester Mixtures. <i>Drug Metabolism and Disposition</i> , 2002, 30, 924-930.	3.3	86
311	Apricot Extract Inhibits the P-gpâ€‘Mediated Efflux of Talinolol. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 2539-2548.	3.3	26
312	Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. <i>International Journal of Pharmaceutics</i> , 2002, 232, 183-192.	5.2	146
313	Intestinal absorption characteristics of the low solubility thiocarboxanilide UC-781. <i>International Journal of Pharmaceutics</i> , 2002, 234, 113-119.	5.2	24
314	Title is missing!. <i>Magyar AprÃ³vad KÃ¶zlemÃ©nyek</i> , 2002, 68, 591-601.	1.4	60
315	Determination of partial solubility parameters of five benzodiazepines in individual solvents. <i>International Journal of Pharmaceutics</i> , 2001, 228, 199-207.	5.2	26
316	Thermal characterization of the antiviral drug UC-781 and stability of its glass. <i>Thermochimica Acta</i> , 2001, 366, 61-69.	2.7	8
317	Investigation of thermal properties of glassy itraconazole: identification of a monotropic mesophase. <i>Thermochimica Acta</i> , 2001, 376, 175-181.	2.7	100
318	Melting behavior of pure polyethylene glycol 6000 and polyethylene glycol 6000 in solid dispersions containing diazepam or temazepam: a DSC study. <i>Thermochimica Acta</i> , 2001, 380, 153-164.	2.7	35
319	New bis(SATE) prodrug of AZT 5â€²â€‘monophosphate: In vitro antiâ€‘HIV activity, stability, and potential oral absorption. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 448-463.	3.3	32
320	Synthesis and characterisation of inulin-azo hydrogels designed for colon targeting. <i>International Journal of Pharmaceutics</i> , 2001, 213, 143-152.	5.2	53
321	Characterization of glassy itraconazole: a comparative study of its molecular mobility below Tg with that of structural analogues using MTDSC. <i>International Journal of Pharmaceutics</i> , 2001, 213, 163-173.	5.2	67
322	Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. <i>European Journal of Pharmaceutical Sciences</i> , 2001, 12, 261-269.	4.0	370
323	Chloroquine accumulates in breast-milk cells: potential impact in the prophylaxis of postnatal mother-to-child transmission of HIV-1. <i>Aids</i> , 2001, 15, 2205-2207.	2.2	27
324	In Vitro, Ex Vivo, and In Situ Intestinal Absorption Characteristics of the Antiviral Ester Prodrug Adefovir Dipivoxil. <i>Journal of Pharmaceutical Sciences</i> , 2000, 89, 1054-1062.	3.3	34

#	ARTICLE	IF	CITATIONS
325	Toxicological investigations of the effects carboxymethylcellulose on ciliary beat frequency of human nasal epithelial cells in primary suspension culture and in vivo on rabbit nasal mucosa. <i>International Journal of Pharmaceutics</i> , 2000, 205, 43-51.	5.2	32
326	Safety assessment of selected cyclodextrins effect on ciliary activity using a human cell suspension culture model exhibiting in vitro ciliogenesis. <i>International Journal of Pharmaceutics</i> , 2000, 193, 219-226.	5.2	42
327	Species-dependent and site-specific intestinal metabolism of ester prodrugs. <i>International Journal of Pharmaceutics</i> , 2000, 205, 93-100.	5.2	52
328	Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. <i>European Journal of Pharmaceutical Sciences</i> , 2000, 10, 311-322.	4.0	187
329	Nasal toxicological investigations of Carbopol 971P formulation of apomorphine: effects on ciliary beat frequency of human nasal primary cell culture and in vivo on rabbit nasal mucosa. <i>European Journal of Pharmaceutical Sciences</i> , 2000, 9, 387-396.	4.0	35
330	Scintigraphic evaluation in rabbits of nasal drug delivery systems based on carbopol 971p [®] and carboxymethylcellulose. <i>Journal of Controlled Release</i> , 2000, 68, 207-214.	9.9	57
331	Hydration Changes Implicated in the Remarkable Temperature-Dependent Membrane Permeation of Cyclosporin A. <i>Biochemistry</i> , 2000, 39, 7621-7630.	2.5	37
332	Use of Caco-2 cells and LC/MS/MS to screen a peptide combinatorial library for permeable structures. <i>International Journal of Pharmaceutics</i> , 1999, 177, 103-115.	5.2	58
333	Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA. <i>International Journal of Pharmaceutics</i> , 1999, 186, 127-136.	5.2	27
334	In vitro transport and uptake of protohypericin and hypericin in the Caco-2 model. <i>International Journal of Pharmaceutics</i> , 1999, 188, 81-86.	5.2	23
335	Title is missing!. <i>Magyar Árvad Kézlönyek</i> , 1999, 57, 493-507.	1.4	18
336	Inhibition of intestinal metabolism of the antiviral ester prodrug bis(POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study. <i>Pharmaceutical Research</i> , 1999, 16, 1035-1040.	3.5	23
337	Effects of pharmaceutical compounds on ciliary beating in human nasal epithelial cells: a comparative study of cell culture models. <i>Pharmaceutical Research</i> , 1999, 16, 1380-1385.	3.5	30
338	Comparison of the disposition of ester prodrugs of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine [PMEA] in Caco-2 monolayers. <i>Pharmaceutical Research</i> , 1998, 15, 239-245.	3.5	10
339	Carrier mechanisms involved in the transepithelial transport of bis(POM)-PMEA and its metabolites across Caco-2 monolayers. <i>Pharmaceutical Research</i> , 1998, 15, 1168-1173.	3.5	22
340	Stability of UC-781, in intestinal mucosal homogenates of the rat, rabbit, and pig. <i>Pharmaceutical Research</i> , 1998, 15, 1799-1802.	3.5	2
341	Application of the thermodynamics of mobile order and disorder to explain the solubility of temazepam in aqueous solutions of polyethylene glycol 6000. <i>International Journal of Pharmaceutics</i> , 1998, 164, 81-89.	5.2	12
342	Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30. <i>International Journal of Pharmaceutics</i> , 1998, 164, 67-80.	5.2	169

#	ARTICLE	IF	CITATIONS
343	Drug absorption studies of prodrug esters using the Caco-2 model: evaluation of ester hydrolysis and transepithelial transport. International Journal of Pharmaceutics, 1998, 166, 45-53.	5.2	58
344	In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation. International Journal of Pharmaceutics, 1998, 169, 105-113.	5.2	39
345	Inulin hydrogels. I. Dynamic and equilibrium swelling properties. International Journal of Pharmaceutics, 1998, 172, 127-135.	5.2	64
346	Inulin hydrogels. II. In vitro degradation study. International Journal of Pharmaceutics, 1998, 172, 137-145.	5.2	45
347	Antiretroviral Efficacy and Pharmacokinetics of Oral Bis(isopropoxyloxycarbonyloxymethyl)9-(2-Phosphonylmethoxypropyl)adenine in Mice. Antimicrobial Agents and Chemotherapy, 1998, 42, 1568-1573.	3.2	135
348	Determination of Chloroquine and Desethylchloroquine in Biological Samples Using Perfusion Chromatography and Fluorescence Detection. Journal of Liquid Chromatography and Related Technologies, 1997, 20, 1103-1113.	1.0	6
349	Use of Azo Polymers for Colon-Specific Drug Delivery. Journal of Pharmaceutical Sciences, 1997, 86, 1321-1327.	3.3	103
350	Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharmaceutical Research, 1997, 14, 492-496.	3.5	48
351	Inulin hydrogels as carriers for colonic drug targeting: I. Synthesis and characterization of methacrylated inulin and hydrogel formation. Pharmaceutical Research, 1997, 14, 1730-1737.	3.5	69
352	THE BELGIAN SOCIETY FOR CELL BIOLOGY. IN VITRO MODELS OF ENDOTHELIAL AND EPITHELIAL BARRIERS: DEVELOPMENT, CELL BIOLOGY AND PHARMACOLOGICAL APPLICATIONS 39th ORDINARY MEETING. Cell Biology International, 1997, 21, 511-535.	3.0	0
353	In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. Pharmaceutical Research, 1996, 13, 891-895.	3.5	25
354	Transport of Artemisinin and Sodium Artesunate in Caco-2 Intestinal Epithelial Cells. Journal of Pharmaceutical Sciences, 1996, 85, 577-579.	3.3	68
355	Determination of Artesunate by Capillary Electrophoresis with Low UV Detection and Possible Applications to Analogues. Journal of Chromatographic Science, 1996, 34, 276-281.	1.4	12
356	High Speed HPLC Determination of Bis(pivaloyloxymethyl)-PMEA and Its Degradation Products, Mono(POM)-PMEA and PMEA. Journal of Liquid Chromatography and Related Technologies, 1996, 19, 2271-2283.	1.0	3
357	Peptidyl Dipeptidase A-Catalyzed Metabolism of Delta Sleep-Inducing Peptide in Bovine Brain Microvessel Endothelial Cells: A Cell Culture Model of the Blood-Brain Barrier. Biochemical and Biophysical Research Communications, 1995, 210, 987-994.	2.1	5
358	Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1994, 658, 311-317.	1.7	35
359	Napsamycins, new Pseudomonas active antibiotics of the mureidomycin family from Streptomyces sp. HIL Y-82, 11372.. Journal of Antibiotics, 1994, 47, 595-598.	2.0	88
360	Chloroquine pharmacokinetic data during chronic daily treatment. European Journal of Clinical Pharmacology, 1993, 44, 409-410.	1.9	2

#	ARTICLE	IF	CITATIONS
361	Diminished sedation during diazepam treatment for chloroquine intoxication. International Journal of Clinical Pharmacy, 1993, 15, 83-85.	1.4	7
362	Evidence for a Polarized Efflux System in Caco-2 Cells Capable of Modulating Cyclosporine A Transport. Biochemical and Biophysical Research Communications, 1993, 197, 360-365.	2.1	165
363	Stereoselective Pharmacokinetic Properties of Chloroquine and De-Ethyl-Chloroquine in Humans. Clinical Pharmacokinetics, 1993, 24, 259-269.	3.5	43
364	A Microassay Method for the Determination of Theophylline in Biological Samples Using HPLC with Electrochemical Detection. Journal of Liquid Chromatography and Related Technologies, 1992, 15, 1303-1313.	1.0	5
365	Transplacental Distribution of Chloroquine in Sheep. Developmental Pharmacology and Therapeutics, 1991, 17, 191-199.	0.2	9
366	HPLC Method for the Determination of Chloroquine and its Main Metabolite in Biological Samples. Journal of Liquid Chromatography and Related Technologies, 1990, 13, 1203-1213.	1.0	18